RNXT · XBRL financial data

RenovoRx financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RNXT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	43	1,123
Cost of revenue	—	—	—	0	327
Gross profit	—	—	—	43	796
Research and development	3,039	4,301	5,667	6,025	6,269
Selling, general and administrative	—	—	5,729	4,988	7,037
General and administrative	2,632	5,649	5,729	—	—
Total operating expenses	5,671	9,950	11,396	11,013	13,306
Operating income (loss)	(5,671)	(9,950)	(11,396)	(10,970)	(12,510)
Other income (expense)	119	4	—	—	—
Income tax expense (benefit)	—	—	—	—	2
Net income (loss)	(6,324)	(9,889)	(10,232)	(8,814)	(11,168)
Earnings per share, basic USD per share	(1.21)	(1.09)	(0.99)	(0.40)	(0.32)
Earnings per share, diluted USD per share	—	(1.09)	(0.99)	(0.40)	(0.32)
Weighted average shares, basic thousands of shares	5,217	9,052	10,291	22,271	35,333
Weighted average shares, diluted thousands of shares	—	9,052	10,291	22,271	35,333

Fiscal years (RNXT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	15,192	4,391	1,173	7,154	7,024
Marketable securities	—	2,049	—	—	—
Accounts receivable	—	—	—	43	139
Inventory	—	—	—	0	189
Prepaid and other current assets	1,089	825	192	—	—
Total current assets	16,281	7,265	1,466	7,828	7,893
Property and equipment, net	—	—	—	12	12
Right-of-use asset	—	—	—	278	190
Total assets	16,287	7,265	1,466	8,118	8,095
Accounts payable	525	534	561	586	799
Accrued liabilities	413	568	614	1,323	1,163
Total current liabilities	938	1,102	1,175	1,909	1,962
Lease liability, non-current	—	—	—	212	107
Total liabilities	938	1,102	4,466	3,640	2,673
Accumulated deficit	(21,284)	(31,173)	(41,405)	(50,219)	(61,387)
Total stockholders' equity	15,349	6,163	(3,000)	4,478	5,422
Total liabilities and equity	16,287	7,265	1,466	8,118	8,095
Common shares outstanding (cover page) thousands of shares	9,029	9,100	16,866	36,547	45,053

Fiscal years (RNXT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(6,324)	(9,889)	(10,232)	(8,814)	(11,168)
Stock-based compensation	147	644	1,078	1,174	1,267
Net cash from operating activities	(5,916)	(8,811)	(10,258)	(9,125)	(10,973)
Purchases of property and equipment	—	—	—	12	2
Net cash from investing activities	(15)	(2,032)	2,032	(12)	(2)
Proceeds from issuing common stock	14,563	—	5,000	15,016	12,102
Proceeds from issuing equity	—	—	38,300	59,200	71,400
Net cash from financing activities	19,328	42	5,008	15,118	10,845
Net change in cash	13,397	(10,801)	(3,218)	5,981	(130)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
RenovoRx	9,479	909	(2,867)*	45.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Nephros	4,697	6,017	681*	10.9M	—	Q2 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026
electroCore	8,501	9,450	(3,518)*	9.0M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
DarioHealth	6,634	not reported	(6,083)*	9.8M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Anteris Technologies Global	249,904	1,009	(20,797)*	97.5M	12.0 quarters	Q2 FY26 10-QJun 30, 2026
Femasys	1,444	332	(3,936)*	8.4M	0.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.